

CKD Biomarkers: Focusing on the Future
November 1 -2, 2022
Hyatt Regency Orlando
Manatee Spring I, Orlando, FL

Day 1- Nov. 1	Item
3:00 – 3:15pm	Welcome
3:15 – 4:45pm	Rapid Fire Sessions – Review of BioCon findings presented by BioCon investigators. What’s been found? What does it mean? Where does it lead? <ul style="list-style-type: none"> - Metabolomics (including pediatrics) <i>Michelle Denburg, MD, MSCE</i> - Proteomics <i>Rajat Deo, MD, MTR</i> - Targeted Markers (including pediatrics) <i>Michael Shlipak, MD, MPH</i>
4:45 – 5:00 pm	Break
5:00 – 7:00pm	Networking and poster session (Peacock Spring) <ul style="list-style-type: none"> - Informational posters describing BioCon data resources, and research posters on CKD biomarkers - Hors d’oeuvres and cash bar

Day 2- Nov. 2	Item												
8:30 – 9:30 am	1:1 mentoring sessions with BioCon Investigators (Coral Spring and Manatee Spring I) (15-20 min blocks) / Breakfast												
9:30 – 10:30 am	CKD Biomarkers and the -omics world <i>Morgan Grams MD, PhD; Eugene Rhee, MD; Ruth Dubin, MD</i>												
10:30 – 10:45 am	Break												
10:45 – 11:30 am	How to get involved with BioCon Data <i>Michelle Denburg, MD, MSCE; Joachim Ix, MD</i> <ul style="list-style-type: none"> - How to get data access and best share resources - Opportunities for research and writing using BioCon data - Panel of early stage investigators who have used Biocon data and lessons learned 												
11:30 – 12:45 pm	Lunch break (attendees to have lunch on their own)												
12:45 – 1:30 pm	Lessons Learned from Central Lab <i>Joseph Bonventre, MD, PhD</i> what to look out for in biomarker research; things to be aware of; issues that arise in biomarker assays <ul style="list-style-type: none"> - 15 minute Q&A 												
1:30 – 3:30pm	Biomarker Think Tank – Panelists will discuss their perspectives on CKD biomarker research and future directions in the field (~10 minutes per panelist), followed by moderator led discussion <u>Panel participants:</u> <table style="width: 100%; border: none;"> <tr> <td>Nicholas King, MS</td> <td>Critical Path Institute</td> </tr> <tr> <td>Stefan Sultana, MD</td> <td>AstraZeneca</td> </tr> <tr> <td>Aliza Thompson, MD</td> <td>U.S. Food and Drug Administration</td> </tr> <tr> <td>Frank Dieterle, PhD</td> <td>Novartis</td> </tr> <tr> <td>Paul Conway</td> <td>American Association of Kidney Patients</td> </tr> <tr> <td>Katherine T Landschulz, PhD</td> <td>Labcorp Drug Development</td> </tr> </table>	Nicholas King, MS	Critical Path Institute	Stefan Sultana, MD	AstraZeneca	Aliza Thompson, MD	U.S. Food and Drug Administration	Frank Dieterle, PhD	Novartis	Paul Conway	American Association of Kidney Patients	Katherine T Landschulz, PhD	Labcorp Drug Development
Nicholas King, MS	Critical Path Institute												
Stefan Sultana, MD	AstraZeneca												
Aliza Thompson, MD	U.S. Food and Drug Administration												
Frank Dieterle, PhD	Novartis												
Paul Conway	American Association of Kidney Patients												
Katherine T Landschulz, PhD	Labcorp Drug Development												
3:30 pm	Adjourn												